多重系统缩 - 一个临床病理学更新
1Institute of Clinical Neurobiology, Vienna, Austria.
Free neuropathology
|June 7, 2023
概括
多重系统缩 (MSA) 是一种致命的神经退行性疾病,其特点是α-synuclein沉积物. 研究正在推进对其复杂病原学的理解,并探索这种无法治愈的疾病的新治疗策略.
科学领域:
- 神经科学是一个神经科学.
- 病理学 病理学 病理学
- 遗传学 遗传学 是一个
背景情况:
- 多重系统缩 (MSA) 是一种致命的,成人发作的神经退行性疾病,病因不明.
- 临床上,它呈现出对Levodopa无反应的帕金森症,小脑,运动和自主功能障碍.
- MSA是一种α-synucleinopathy,涉及多个神经系统区域的glioneuronal退化.
研究的目的:
- 阐明了多系统性缩 (MSA) 的进展背后的分子机制.
- 了解涉及α-synuclein (αSyn) 传播和细胞功能障碍的病变.
- 突出需要多学科研究,以开发有效的治疗方法.
主要方法:
- 用小鼠模型和人类患者进行的研究,以了解疾病的进展.
- 对α-synuclein (αSyn) 沉积和细胞间传播的分析.
- 对包括氧化应激和神经炎症在内的致病机制的当前理解的审查.
主要成果:
- MSA的发病包括类αSyn传播,氧化应激,蛋白质和线粒体功能障碍以及神经炎症.
- 疾病的进展导致神经退行,脱髓化和多系统参与.
- 用生物标志物改善了诊断准确性,尽管严重的痴呆症很少见.
结论:
- 多个系统缩 (MSA) 的发病过程复杂,涉及多个相互作用的分子和细胞通路.
- 尽管诊断得到了改进,临床试验正在进行中,但仍然缺乏有效的疾病修饰疗法.
- 迫切需要进行多学科研究,以揭示开发MSA有效治疗方法的遗传和分子基础.
相关概念视频
01:15Parkinson's Disease: Overview
612
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
612
01:22Lysosomal Hydrolases
3.9K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.9K
01:26Alzheimer's Disease: Overview
536
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
536
01:20Myasthenia Gravis: Overview and Treatment
1.6K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.6K
01:24Parkinson's Disease: Treatment
305
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
305